Recombinant tissue-type plasminogen activator (r-tPA) (or its derivate Tenecteplase) is the only pharmacological treatment at the acute phase of ischemic stroke, based on its ability to convert plasminogen into active plasmin and thus to promote thrombolysis [1]. This evidence concerns the gene PLG and ischemic stroke.